In secondary analyses of cardiovascular outcome trials, SGLT2 inhibitors and GLP-1 receptor agonists have demonstrated renoprotection among people with type 2 diabetes [8, 9]. Here, SLC5A2 is linked to type 2 diabetes mellitus.